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Bacterial infections are very common and represent one of the
most important reasons of progression of liver failure, develop-
ment of liver-related complications, and mortality in patients
with cirrhosis. In fact, bacterial infections may be a triggering fac-
tor for the occurrence of gastrointestinal bleeding, hypervolemic
hyponatremia, hepatic encephalopathy, kidney failure, and devel-
opment of acute-on-chronic liver failure. Moreover, infections are
a very common cause of repeated hospitalizations, impaired
health-related quality of life, and increased healthcare costs in
cirrhosis. Bacterial infections develop as a consequence of
immune dysfunction that occurs progressively during the course
of cirrhosis. In a signiﬁcant proportion of patients, infections are
caused by gram-negative bacteria from intestinal origin, yetJournal of Hepatology 20
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E-mail address: pgines@clinic.ub.es (P. Ginès).gram-positive bacteria are a frequent cause of infection, particu-
larly in hospitalized patients. In recent years, infections caused by
multidrug-resistant bacteria are becoming an important clinical
problem in many countries.
The reduction of the negative clinical impact of infections in
patients with cirrhosis may be achieved by a combination of pro-
phylactic measures, such as administration of antibiotics, to
reduce the occurrence of infections in high-risk groups together
with early identiﬁcation and management of infection once it
has developed. Investigation on the mechanisms of altered gut
microﬂora, translocation of bacteria, and immune dysfunction
may help develop more effective and safe methods of prevention
compared to those that are currently available.Moreover, research
on biomarkers of early infection may be useful in early diagnosis
and treatment of infections.
The current manuscript reports an in-depth review and a position
statement on bacterial infections in cirrhosis.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.14 vol. 60 j 1310–1324
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Fig. 1. Mortality rate caused by bacterial infections in cirrhosis in the last
decades. 1-month and 1-year mortality rates were higher before than after 2000,
although differences were not statistically signiﬁcant. Modiﬁed from [6].and currently represent one of the most common causes of
admission to hospital in these patients and a major challenge
for physicians caring for patients with liver diseases. Despite
the recent improvements in the knowledge of pathogenesis, pre-
vention, and management, bacterial infections still represent a
major cause of morbidity and mortality among patients with cir-
rhosis. On this background, the European Association for the
Study of the Liver (EASL) decided to hold a Special Conference
on Bacterial Infections in cirrhosis in May 2013 in Barcelona.
The conference gathered a large number of clinical and basic
scientists as well as clinicians with special interest on the topic
who had presentations and extensive discussions on the main
areas of the ﬁeld. The current manuscript represents a position
statement that summarizes the different areas that were
discussed during the Conference and includes expert opinions
on important aspects of the management of bacterial infections
in cirrhosis.
Key Points
• The incidence and severity of infection in cirrhosis is 
greater than in the population without cirrhosis
• Infection with multiresistant organisms is common in 
cirrhosis and its occurrence is associated with higher 
mortality rates than in patients without cirrhosis
• The end-organ damaging effect of bacterial infection 
is greater in patients with cirrhosis due to altered 
sensitivity, which often culminates in acute-on-chronic 
liver failure
• Delays in the diagnosis and start of treatment results in 
higher mortality particularly in hypotensive patients with 
cirrhosis
• In patients with spontaneous bacterial peritonitis, the 
addition of albumin to antibiotics reduces mortality
• Primary prophylaxis of spontaneous bacterial peritonitis 
with norfloxacin is indicated in patients with variceal 
bleeding, severely decompensated cirrhosis, and those 
with ascites protein concentration of <15 g/L
• In patients with variceal bleeding, intravenous 
administration of 3rd generation cephalasporins improves 
survival
• Administration of norfloxacin to prevent recurrence of 
spontaneous bacterial peritonitis reduces mortality in 
cirrhosis
• Research into the mechanisms associated with 
increased risk of infection in cirrhosis, better use of 
current therapeutic strategies, development of rapid 
and accurate diagnostic tools, and development of 
new strategies to modulate the gut-liver interaction are 
urgently neededJournal of Hepatology 2014Clinical aspects of bacterial infections in cirrhosis and the
problem of multiresistant bacteria
Patients with cirrhosis have increased risk of developing bacterial
infections [1,2]. Infections are present at admission or develop
during hospitalization in 25–35% of patients [3,4], an incidence
that is 4–5 fold higher than that observed in the general popula-
tion. Spontaneous bacterial peritonitis (SBP) and urinary tract
infections are the most frequent infections followed by pneumo-
nia, skin and soft tissue infections, and bacteremia. Clinical fac-
tors associated with an increased risk of infection are poor liver
function, variceal bleeding, low ascitic ﬂuid protein levels, prior
SBP and hospitalization [1,2]. Severity of infection is also higher
in patients with cirrhosis who are more likely to die from sepsis
than individuals without cirrhosis. Bacterial infection increases
3.75 fold the probability of death of patients with decompensated
cirrhosis, reaching 30% at 1 month and 63% at 1-year (Fig. 1) [5,6].
Enterobacteriaceae and non-enterococcal streptococci cause
the majority of spontaneous infections in cirrhosis. As a conse-
quence, b-lactams and quinolones have been widely used in their
treatment and prevention [1,2]. This feature and the increasing
level of invasiveness to which patients with cirrhosis are cur-
rently submitted have induced important changes in the epide-
miology of bacterial infections in cirrhosis. Spontaneous and
secondary infections caused by non-classical pathogens or multi-
drug resistant (MR) bacteria are nowadays increasingly reported
in this population [1,4].
Infections by multiresistant bacteria in the general population and
cirrhosis
MR bacteria are pathogens resistant to 3 or more of the main anti-
biotic families, including b-lactams [7]. The main MR bacteria are
extended-spectrum b-lactamase-producing Enterobacteriaceae
(ESBL), non-fermentable gram-negative bacilli such as Pseudomo-
nas aeruginosa, Stenotrophomonasmaltophilia or Acinetobacter bau-
manii, methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-susceptible or resistant enterococci (VSE, VRE). Infec-
tions caused by these bacteria have increased in the general popu-
lationmainlydue to thedispersionof the so-calledhigh-risk clones
not only in the hospitals but also in the community. These clones
are speciﬁc bacteria able to acquire several resistancemechanisms
and virulence determinants. Moreover, they efﬁciently colonize
different human niches, including the gastrointestinal tract [8].vol. 60 j 1310–1324 1311
Table 1. Prevalence and clinical impact of different multiresistant bacterial infections in cirrhosis in several geographical areas.
Country, yr [Ref.] Prevalence of multiresistant bacteria Clinical impact 
Korea, 2006 [10] 29% ESBL-producing Enterobacteriaceae* No impact
Spain, 2008 [11] 6% ESBL-producing Enterobacteriaceae No impact
Italy, 2008 [12] 8% ESBL-producing Enterobacteriaceae Higher initial treatment failure
No impact on mortality
Korea, 2009 [13] 15% ESBL-producing Enterobacteriaceae Independent predictor of 30-day mortality
Korea, 2009 [14, 15] 4-7.5% ESBL-producing Enterobacteriaceae Higher initial treatment failure
Higher hospital and 30-day mortality 
Turkey, 2009 [16] 2% ESBL-producing Enterobacteriaceae
1% Pseudomonas aeruginosa
No data
France, 2009 [17] 8% MRSA**
5% VSE#
4% ESBL-producing Enterobacteriaceae
No data
Germany, 2009 [18] 10% VSE Higher initial treatment failure
Higher hospital mortality
Italy, 2010 [9] 20% ESBL-producing Enterobacteriaceae
7% MRSA
Higher hospital mortality
Spain, 2012 [19] 6% ESBL-producing Enterobacteriaceae
2% Pseudomonas aeruginosa
2% Acinetobacter baumannii
1% VSE
Independent predictor of mortality at 30 days
Spain, 2012 [4] 8-9% ESBL-producing Enterobacteriaceae
3% Pseudomonas aeruginosa
3-4% MRSA
3-7% VSE
Lower infection resolution
Higher risk of septic shock
Higher hospital mortality
USA, 2012 [20] 9% VRE&
6.5% ESBL-producing Enterobacteriaceae
5% MRSA
No data
⁄ESBL, extended-spectrum b-lactamase-producing Enterobacteriaceae (bacteria with chromosomal b-lactamases are also included).
⁄⁄MRSA, methicillin-resistant Staphylococcus aureus.
#VSE, vancomycin-susceptible enterococci.
&VRE, vancomycin-resistant enterococci.
Position PaperMultiple studies from very different geographical areas have
recently reported an increased prevalence of infections caused
by MR bacteria in cirrhosis [4,9–20]. The site of acquisition of
infection determines the risk of MR bacterial infection with
higher rates of MR bacteria in infections acquired in the health-
care environment: 23–39% in nosocomial infections, 14–41% in
healthcare-associated (HCA) episodes and 0–16% in infections
acquired in the community [4,9].
Epidemiological pattern of MR bacteria differs markedly
among geographical areas and even among hospitals. Regular
assessment is therefore recommended [1,21]. ESBL-producing
Enterobacteriaceae are predominant in South Europe and Asia
[4,9–19], while MRSA and VRE are frequently isolated in centers
from USA or South America [20].
Carbapenemase-producing K. pneumoniae are also being
increasingly isolated in some centers in Italy [22]. Table 1 shows
the different prevalence of MR bacteria in infections in patients
with cirrhosis in different countries.
Clinical outcome of nosocomial and multiresistant bacterial
infections in cirrhosis
Early studies reported conﬂicting results regarding the prognosis
of nosocomial infections in cirrhosis. Some showed very high
mortality rates (59–67%) while others reported ﬁgures similar
to those observed in community-acquired infections (Table 1)
[13,23,24]. Recent data from Spain clearly support the former
contention [4]. The study included 669 infections from 2 series1312 Journal of Hepatology 2014(2005–2007 and 2010–2011). Hospital mortality rate of nosoco-
mial infections (25–48% respectively) was signiﬁcantly higher
than that observed in health-care associated (9–23% respectively)
and community-acquired episodes (7–21% respectively). The
same study also demonstrated that infections caused by MR bac-
teria are more common among nosocomial infections, have a
poorer prognosis than those caused by susceptible bacteria with
higher rates of treatment failure and associated septic shock (26%
vs. 10% respectively) and higher hospital mortality (25% vs. 12%
respectively) [4].Pathogenesis of bacterial infections
The following part focuses on the interaction of gut microbiota,
intestinal permeability, bacterial translocation (BT) and immune
deﬁciency which may be acquired or conferred by genetic sus-
ceptibility, acting in concert as pathophysiological culprit for
most bacterial infections seen in cirrhosis (Fig. 2) [25]. BT occurs
in healthy conditions but is increased in cirrhosis and hence,
should be called pathological BT.
Gut microbiota
The host needs to keep gut bacteria under very tight control to
prevent pathological BT for which the immune system of the
gut-associated lymphatic tissue plays a crucial role. On the other
hand, intestinal bacteria contribute to symbiosis by educatingvol. 60 j 1310–1324
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Fig. 2. Pathogenesis of bacterial infections in cirrhosis. The risk of bacterial
infection in cirrhosis is due to multiple factors that include liver dysfunction,
portosystemic shunting, gut dysbiosis, increased bacterial translocation, cirrho-
sis-associated immune dysfunction (AID) and genetic factors.
JOURNAL OF HEPATOLOGYand maintaining the host immune system. A dysbalance of this
delicate homeostasis between host and microbiome can lead to
disease [3,26,27].
Alterations in the microbiome can either occur as quantitative
(intestinal bacterial overgrowth – IBO) or qualitative (dysbiosis)
changes. IBO is a common feature in patients with liver cirrhosis
and occurs predominantly in the small intestine [28–30]. IBO is
multifactorial, and contributing factors include modulation of
gastric acid secretion, decrease in intestinal motility, lack of bile
constituents and antimicrobial peptides as well as portal hyper-
tension [31–36]. Patients with cirrhosis and IBO more frequently
have SBP than patients without bacterial overgrowth [31]. Exper-
imental IBO itself can result in microbial translocation and liver
inﬂammation [37] emphasizing the importance of quantitative
microbiome changes. Reducing the intestinal bacterial burden
with antibiotics ameliorates experimental liver disease [38,39]
and, decreases the liver disease severity [40,41] and infectious
complications in patients with advanced cirrhosis [42]. Qualita-
tive changes of the human microbiome have been characterized
by deep pyrosequencing. Several studies described the microbial
taxonomy in patients with early and end-stage liver disease [43]
due to chronic hepatitis B infection [44,45], alcohol [44,46], and
NAFLD/NASH [47,48]. Whether these qualitative disturbances
results in factious complications will need further investigation.
Intestinal barrier dysfunction
Increased intestinal permeability has been demonstrated by
complementary methods and shown to be particularly present
in advanced stages of disease and septic complications. Tight
junctions (TJ) between epithelial cells limit paracellular perme-
ation and thus translocation of bacterial products. Alterations in
TJ proteins are present in cirrhosis and most likely loosen TJ-func-
tion [49,50]. As for invasion of viable bacteria however, transcy-
tosis appears to represent the major route but is poorly deﬁned
in cirrhosis. One of the key regulators modulating TJ and transcy-
tosis is tumor necrosis factor-a, which is increased in the
gut-associated lymphatic tissue in advanced cirrhosis [51,52].
Secreted mediators that limit the direct contact of intestinal bac-Journal of Hepatology 2014teria to the epithelial surface and shown to be deﬁcient in cirrho-
sis include IgA [53], biliary lipids [54], and antimicrobial peptides
[35]. Compromised Paneth cell antimicrobial host defense is
observed in experimental cirrhosis being associated with
decreased mucosal killing activity against invading bacteria
[35]. Expression of the antimicrobial protein Reg3g, which main-
tains a physical barrier between the epithelial cell surface and
intestinal microbes [47], was suppressed in intestinal biopsies
from patients with chronic alcohol abuse [38].
Genetic predisposition to bacterial infections
Extracellular bacteria are recognized by membrane-bound Toll-
like receptors (TLR) and intracellular Nod-like receptors (NLR),
including NOD2 and NLRP3, which lead to activation of nuclear
factor NFKb and stimulate the release of antimicrobial peptides.
TLR1 and TLR2 recognize tri-acylated lipoprotein from gram-
positive bacteria, TLR4 detects lipopolysaccharide (LPS), and
NOD2 senses muramyl dipeptide, a cell wall component of
gram-negative bacteria. Of note, the presence of genetic variation
in the NOD2, NLRP3, and TLR4 genes has been demonstrated to
confer susceptibility to Crohn’s disease [55], graft-vs.-host dis-
ease after bone marrow transplantation [56] and for mortality
in patients with sepsis [57]. Interestingly, TLR4-deﬁcient mice
have less severe fulminant hepatitis and ischemic-reperfusion
injury compared to normal mice [58,59]. In cirrhosis [60], carriers
of NOD2 risk variants displayed a higher risk for SBP and death.
This association was replicated for culture-positive SBP; an inter-
esting ﬁnding in this study was that patients with NOD2 variants
presented more often with variceal bleeding and hepatocellular
carcinoma [61]. In addition, SBP was more frequent in patients
with cirrhosis who carry TLR2 risk variants, which might be par-
ticularly important when gram-positive organisms, become a
major cause of SBP [62]. In multivariate analysis, the simulta-
neous presence of variants in both NOD and TLR2 genes indicates
a particularly high risk for SBP (OR = 11) and is also associated
with surrogate markers for abnormal intestinal permeability
and BT. Finally, in retrospective analysis, an association between
a TLR4 polymorphism and increased infection rates in cirrhosis
and more pronounced stimulation of cytokine expression was
described [63]. These studies indicate that common gene variants
linked to impaired mucosal barrier function and BT represent
genetic risk factors for SBP and other infections in patients with
liver cirrhosis.
Immune dysfunction
Cirrhosis associated immune dysfunction (CAID) involves a state
of immunodeﬁciency, and in parallel a state of persistent activa-
tion of the immune system cells with production of pro-inﬂam-
matory cytokines [64–66]. Immunodeﬁciency affects both the
innate and the adaptive arm of the immune systemwith a myriad
of defects. Except for monocytes, cirrhosis leads to reduced num-
bers of circulating immune system cells, which is particularly
profound for neutrophils, naïve Th- and Tc-cells, as well as
CD27+ memory B-cells [64,67]. Coupled with their reduced num-
bers, mononuclear phagocytic cells and neutrophils show
reduced abilities of phagocytosis and mobilization, T and B cells
show hypo-proliferation in response to mitogens and CD40/
TLR9, respectively, and NK cells display low cytotoxic activity
[64,67–70]. Additionally, cirrhosis results in reticuloendothelialvol. 60 j 1310–1324 1313
Table 2. Deﬁnition of organ failures in patients with cirrhosis. (A) Organ/systems whose functions are assessed by the Chronic Liver Failure (CLIF)-Sequential Assessment
of Organ Failure (SOFA) scale (adapted from [74]). (B) Deﬁnition of the presence or absence of acute-on-chronic liver failure (ACLF) provided by the CANONIC study [76].
Organ failures shown here are those deﬁned in panel A.
The CLIF-SOFA scale
Organ/system 0 1 2 3 4
Liver
Bilirubin (mg/dl) <1.2 ≥1.2-<1.9 ≥2-<5.9 ≥6-<12 ≥12
Kidney
Creatinine (mg/
dl)
<1.2 ≥1.2-<1.9 ≥2-<3.5 ≥3.5-<5 ≥5
Cerebral (HE grade) No HE 1 2 3 4
Coagulation INR <1.1 INR 1.1-1.25 INR 1.26-1.5 INR 1.51-2.5 INR >2.5 or
platelets ≤20x103/μl
Circulation
MAP (mmHg) ≥70 <70 Dopamine ≤5
or
dobutamine
or
terlipressin
Dopamine >5-≤15
or
epinephrine ≤0.1
or
norepinephrine ≤0.1
Dopamine >15
or
epinephrine >0.1
or
norepinephrine >0.1
Lungs
PaO2/FiO2
or
SpO2/FiO2
>400
>512
≤400
>357-≤512
≤300
>214-≤357
≤200
>89-≤214
≤100
≤89
ACLF grade Definition
No • No organ failure
• Single organ failure (liver, coagulation, circulation, lungs) + creatinine <1.5 mg/dl + no hepatic encephalopathy
• Single cerebral failure + creatinine <1.5 mg/dl
1 • Single kidney failure
• Single organ failure (liver, coagulation, circulation, lungs) + creatinine 1.5-≤1.9 mg/dl 
and/or grade 1-2 hepatic encephalopathy
• Single cerebral failure + creatinine 1.5-≤1.9 mg/dl
2 • 2 organ failures
3 • 3 organ failures or more
B
A
The CLIF-SOFA score includes sub-scores ranging from 0 to 4 for each of six components (liver, kidneys, brain, coagulation, circulation, and lungs) with higher scores
indicating more severe organ impairment. Aggregated scores range from 0 to 24 and provide information on overall severity. The use of dobutamine or terlipressin, at any
dose, is sufﬁcient to count a score of 2 for circulation. Doses of catecholamines shown in the Table are lg/kg.min.
The highlighted area in yellow shows the diagnostic criteria for organ failures [This table appears in colour on the web].
HE, hepatic encephalopathy; INR, International Normalized Ratio; MAP, mean arterial pressure; PaO2, partial pressure of arterial oxygen; FIO2, fraction of inspired oxygen;
SpO2, pulse oximetric saturation.
Position Paperdysfunction, due to reduced number of liver reticuloendothelial
mononuclear cells in liver and porto-systemic shunting, which
lower the liver ability to clear intestinal bacteria, as well as
decreased hepatic synthesis of molecules of the innate immune
response, such as complement components and secreted-pattern
recognition receptors [71]. These defects coexist with an induced
expression of activation molecules on the surface of immune cells
and the increased synthesis of pro-inﬂammatory cytokines, espe-
cially by monocytes [72,73].
CAID has a multifactorial pathogenesis, which includes con-
tinuous immune system cells stimulation by microbial- and dam-
age-associated molecular patterns (MAMPs, DAMPs), decreased
hepatic synthesis of trophic factors, hypersplenism and splenic
pooling of immune system cells, and the etiological factors of cir-
rhosis such as alcohol or virus. Furthermore, the continuous
interaction of gut bacteria with stimulation of the immune sys-
tem may lead to exhaustion of the immune response and1314 Journal of Hepatology 2014‘immune paralysis’, which might further increase the risk of bac-
terial infections [65,74].Consequences of bacterial infections
Bacterial infections are a common cause of acute decompensa-
tion of cirrhosis [4]. Among patients with cirrhosis and acute bac-
terial infections some have ‘‘mere’’ decompensated cirrhosis
while others exhibit decompensated cirrhosis associated with
newly developed liver and/or extra-hepatic organ failure(s) [2].
Patients with cirrhosis and ‘‘acute’’ organ failure(s) are at high
risk of short-term death [74,75]. These patients are considered
to have acute-on-chronic liver failure (ACLF) [74]. A large pro-
spective observational study called CANONIC study was recently
performed with the aim of establishing the diagnostic criteria of
ACLF [76]. This study used the CLIF-Sequential Organ Failurevol. 60 j 1310–1324
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Fig. 3. Pathophysiological basis of acute on chronic liver failure and end-organ dysfunction in cirrhosis precipitated by infection.
JOURNAL OF HEPATOLOGYAssessment (SOFA) score to recognize organ failures. The CANO-
NIC study provided a robust deﬁnition of ACLF into three ACLF
grades, with increasing risk of short-term death from grade 1
(22%) to grade 3 (77%) [76]. Table 2A and B describe the scoring
system used and also the diagnostic criteria. Bacterial infection
was the most common precipitating event of ACLF (33%) [76].
Among patients with bacterial infection, ACLF was more common
in patients with SBP or pneumonia than in those with infections
at other sites [9,76]. The pathophysiology and manifestations of
infection-induced organ failure is incompletely understood [2];
the following mechanisms have been suggested (Fig. 3).
Inﬂammation
Bacterial components (e.g., lipopolysaccharide (LPS) a Gram-neg-
ative bacteria byproduct) may cause an excessive pro-inﬂamma-
tory response of the host immune system resulting in tissue
damage (a process called immunopathology) and organ failure
[77]. An excessive production of pro-inﬂammatory molecules
has been shown to occur in vivo and ex vivo in patients [78–87]
and animals [88–90] with cirrhosis. Among infected patients, sys-
temic inﬂammation is more marked in patients with ACLF than in
those without [76]. The susceptibility to LPS-induced liver injury
(assessed by the degree of hepatocyte apoptosis and necrosis) is
higher in animals with cirrhosis than in normal animals
[89,90]. This higher susceptibility in cirrhosis decreases when
high-density lipoprotein administration is used to neutralize
LPS [90,91]. However, infection-induced organ failure may not
be entirely explained by an increased production of pro-inﬂam-
matory molecules (see below).
Several mechanisms related to bacterial infections may lead
to cell necrosis [77]. Dying cells are known to release nuclearJournal of Hepatology 2014molecules (called danger-associated molecular patterns, DAMPs),
which are able to stimulate the innate immune system through
different receptors and trigger inﬂammation [77]. The role of
DAMPs in ACLF-associated inﬂammation requires to be
investigated.
Organ damage
Infection-induced tissue damage may depend not only on the
intensity of the inﬂammatory response per se but also on the
intrinsic capacity of host organs to tolerate (i.e., endure) the
effects of the inﬂammatory response [77]. The capacity of toler-
ance of each organ depends on inducible mechanisms such as
anti-apoptotic pathways, among others [77]. In the context of
Gram-negative infections, normal livers are protected against
LPS-induced, TNF-a-mediated apoptosis because of simultaneous
induction of nuclear factor-jB (NF-jB)-dependent anti-apoptotic
molecules [89]. In contrast, cirrhotic livers are abnormally sus-
ceptible to LPS-induced, TNF-a-mediated apoptosis because NF-
jB-target anti-apoptotic molecules cannot be properly induced
[89]. Therefore, in cirrhosis, infection-induced liver failure may
be related not only to an excessive pro-inﬂammatory response
but also to a decrease in the hepatic capacity of tolerance. The
role of the alteration of tolerance mechanisms in the
development of infection-induced extra-hepatic organ failures
should be investigated in patients and animals with ACLF.
Kidney failure
Bacterial infections [79,92] are well-established triggers of kid-
ney failure in cirrhosis. Patients with SBP without shock who
exhibit the highest pro-inﬂammatory response are those whovol. 60 j 1310–1324 1315
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are at risk of developing kidney failure [79]. Of note, in these
patients, kidney failure frequently develops while resolution of
infection has been obtained by antibiotic therapy [93] suggesting
that organ failure does not result from intrinsic virulence (i.e., tis-
sue damage directly caused by bacteria) but rather extrinsic vir-
ulence (i.e., caused by the excessive inﬂammatory response of the
host) or sepsis-related alterations in hemodynamics [93]. A
potential role for alterations of tolerance mechanisms in the
development of kidney failure [94] has not yet been investigated.
Brain failure
Bacterial infections are common triggers of hepatic encephalopa-
thy [95]. Clinical and experimental data show that infections may
result in brain oedema in patients with cirrhosis. It is currently
uncertain whether this water accumulation is predominantly
intracellular or extracellular. There is some evidence that both
mechanisms combine to cause brain edema and hepatic enceph-
alopathy (HE) [96].
Coagulation failure
Among infected patients with cirrhosis, disseminated intravascu-
lar coagulation (DIC, which can be activated by pro-inﬂammatory
cytokines) is more frequent in patients with ACLF than in those
without [75]. Thrombi in the microvasculature of a vital organ
may play a role in tissue hypoxia [77]. Of note, activation of coag-
ulation may stimulate inﬂammation [77].
Variceal bleeding
Variceal hemorrhage is a well-established risk factor for bacterial
infection in patients with cirrhosis [97]. Moreover, it has been
suggested that conversely bacterial infection might increase the
risk of variceal hemorrhage [98]. This hypothesis needs to be con-
ﬁrmed by future studies.
Adrenal insufﬁciency
Patients with cirrhosis and septic shock (most often classiﬁed as
ACLF grade 3 patients) may have high incidence of relative adre-
nal insufﬁciency (RAI, 51–77%) [99]. The presence of RAI seems to
be associated with poor liver function, kidney failure, refractory
shock and hospital mortality [100]. RAI could result in decreased
corticosteroid-related anti-inﬂammatory mechanisms and conse-
quently unrestricted infection-induced production of pro-inﬂam-
matory molecules. In addition, under stress conditions, defective
corticosteroid production could be associated with decreased
capacity of tolerance of vital organs [77,78].
Recent but limited data suggest that RAI can also occur in
non-critically ill patients with cirrhosis. The reported prevalence
of this entity ranges between 7% and 49% depending on the meth-
odology used for RAI diagnosis [99]. Since serum total cortisol
overestimates the prevalence of RAI in cirrhosis due to low trans-
cortin and albumin concentrations, free cortisol levels have been
suggested as the preferred method for the diagnosis of RAI in this
population [101,102]. Delta total cortisol values, a dynamic diag-
nostic criteria of RAI not affected by changes in transcortin or
albumin levels, can also be used for its diagnosis [103]. In a recent
study involving non-critically ill patients with cirrhosis, RAI was
associated with greater impairment of circulatory and renal func-1316 Journal of Hepatology 2014tion, higher probability of severe sepsis and type-1 HRS and
higher short-term mortality [103]. By contrast, another study
reported a higher risk of death in patients with high free cortisol
levels [102].Early diagnosis and biomarkers
Early diagnosis of bacterial infections is a crucial step in the man-
agement of patients with cirrhosis. Since the presentation and the
initial course of a bacterial infection in some patients with cirrho-
sis may be subtle and not very speciﬁc, clinical suspicion is impor-
tant. Indeed, all hospitalized patients with cirrhosis should be
considered as potentially infected until proven otherwise. There-
fore, a complete work-up should be carried out at admission and
on clinical deterioration of a hospitalized patient in order to detect
a possible infection [1,4]. In addition, a close microbiological sur-
veillance, is needed in patients who are at risk for the develop-
ment of infections caused by MR organisms [1,22,104,105]. It is
well known that bacterial infections can induce systemic inﬂam-
matory response (SIRS). On the basis of conventional criteria
[106], SIRS has been described in 57–70% of infected patients with
cirrhosis [81,107], but these data may underestimate the rate of
SIRS since these patients may have a low heart rate due to the
use of beta blockers and may present an apparently normal white
blood cell count due to hypersplenism. On the other hand, SIRS
may be diagnosed in patients with cirrhosis in the absence of bac-
terial infection since the hyperdynamic circulation, hepatic
encephalopathy, tense ascites and hypersplenism may alter heart
and respiratory rate, temperature and white-cell count. SIRS has
been described in 10–30% of patients with decompensated cirrho-
sis without bacterial infection [83,107]. The evident lack of sensi-
tivity and speciﬁcity of the conventional parameters for the
deﬁnition of SIRS [105,106] makes it difﬁcult to diagnose sepsis
in these patients. Thus, new tools for the diagnosis of bacterial
infections are clearly needed. In this context, it should be men-
tioned that a recent study reported that persistently high levels
of CRP in patients with decompensated cirrhosis are associated
with increased short-term mortality. The predictive value of CRP
was independent from relevant predictive factors, such as MELD
score, and was better than that of SIRS diagnosed by conventional
criteria [108]. Although not demonstrated, it is likely that the high
levels of CRP may indicate a systemic inﬂammatory reaction
linked to hidden bacterial infections and/or persistent bacterial
translocation.
New tools for early detection of the presence and of the severity of
bacterial infections
From a pathophysiological perspective, pathological BT, altered
host response to injury, and impairment in the ability of the
innate immune system to adequately ﬁght off infections are
important [1]. Therefore gut permeability, gut ﬂora, bacterial
products, acute phase proteins, the function of innate immune
cells, cellular receptors and cellular products and molecules
involved in endotoxin presentation and removal are likely targets
for such biomarkers.
Markers of gut barrier dysfunction/bacterial translocation
Increased intestinal permeability is predictive for infection after
variceal haemorrhage [107] and calprotectin levels have beenvol. 60 j 1310–1324
Table 3. Potential tools for early detection. (A) Potential tools for early detection of the presence and the severity of bacterial infections. (B) Potential tools for an early
identiﬁcation of the pathogen and of its susceptibility to antibiotics.
Tool Potential usefulness Limitations
CRP For a cut off value ≥10 ng/ml it has proved to be a useful 
marker to predict the likelihood of clinically signiﬁcant 
bacterial infections in patients with cirrhosis without overt 
infections
For cut off values of 24.7 ng/ml of CRP the area under the 
ROC curve for predicting sepsis was 0.811 in patients with 
cirrhosis
Patients with cirrhosis may present reduced CRP in 
response to infection. Up to 14.8% of patients with 
cirrhosis and bacterial infection may have a baseline 
CRP <10 mg/L.
bacterial translocation are potentially able to induce the 
Infection independent factors like inflammation and
Infection independent factors like inflammation and
synthesis of CRP
CRP levels could remain elevated over time despite the 
resolution of bacterial infection in the majority (62.5%) of 
patients
PCT For cut-off values of 0.49 of PCT the area under the 
ROC curve for predicting sepsis was found to be 0.89 in 
patients with cirrhosis
bacterial translocation are potentially able to induce the 
synthesis of PCT
CRP and PCT In patients with cirrhosis the combination of PCT and CRP 
increased the sensitivity and negative predictive value in 
the detection of infections, compared with CRP on its own, 
by 10 and 5% respectively
The superiority of PCT over CRP in the detection of 
bacterial infections and in the diagnosis of sepsis remains 
controversial and is still a matter of debate in patients with 
cirrhosis
Tool Potential usefulness Limitations
Real time PCR 
assays
Methods for early detection of infection based on multi-
pathogen probe-based real-time PCR system targeting 
DNA sequences of bacteria and fungi directly from whole 
blood sample, without prior incubation or culture steps in 
less than 6 hours
Their sensitivity and speci
DNA from ascitic fluid in patients with cirrhosis compared
ﬁcity for detecting bacterial 
with those of standard cultures were 100% and 91.5%, 
respectively
Concordance with ascitic cultures for species identiﬁcation 
in patients with cirrhosis was 70.6%.
They provide information not entirely interchangeable with 
cultures for pathogen identiﬁcation
Frequent detection of environmental organisms of 
undetermined pathogenicity is currently a limitation. 
They are not superior to blood cultures for pathogen 
identiﬁcation, in an unselected patient population with 
suspected sepsis
They are expensive and time-consuming and they need 
special equipment and technical expertise for DNA 
extraction
DST Methods (based on MALDI-TOF) for early detection of 
resistant bacteria and testing their antibiotic susceptibility 
from blood cultures or other body-sterile fluids cultures.
The reporting time for the direct testing of susceptibility 
for blood cultures by the system ranged from 3.3 to 17.5 
h compared with conventional methods that require 1 or 2 
days
Results still need to be conﬁrmed by conventional methods 
and DST cannot be done or results are not reliable in 
mixed infections (Gram-positive and Gram-negative) or 
infections caused by yeasts
B
A
CRP, C reactive protein; PCT, procalcitonin; DST, direct susceptibility tests; MALDI-TOF, matrix assisted laser desorption ionization – time of ﬂight.
JOURNAL OF HEPATOLOGYshown to correlate with BT [109]. Markers of BT such as endo-
toxin, D-lactate, peptidoglycan and bacterial DNA are elevated
in the serum of patients with cirrhosis [110–112] and may
predict mortality [113–115]. However, bacterial DNA does not
correlate with infection [113].
Markers of innate immune response
Neutrophil function is impaired in cirrhosis, displaying an inade-
quately increased resting oxidative burst with a defect in phago-
cytosis and killing. This is associated with an increase in
mortality and an increased rate of infections. [64,114]. Similar
functional defects have been shown for monocytes and macro-Journal of Hepatology 2014phages [65,115–119]. Whether they can be used as indicators
of susceptibility needs to be tested.
Markers of inﬂammatory response
Procalcitonin (PCT) and C-reactive protein (CRP) are two acute-
phase serum proteins, which are commonly used as early mark-
ers of infection in general population [119]. CRP is mainly pro-
duced by the hepatocytes while PCT is produced ubiquitously
including the liver [119]. Although there is evidence that serum
levels of these acute-phase proteins are not signiﬁcantly lower in
patients with cirrhosis than in other patients [120], patients with
cirrhosis may present reduced CRP and PCT levels, particularlyvol. 60 j 1310–1324 1317
Table 4. Recommended empirical antibiotic treatment for community-acquired and nosocomial bacterial infections in cirrhosis.
Type of infection Community-acquired infections Nosocomial infections*
SBP, SBE and 
spontaneous bacteremia
Cefotaxime 
or ceftriaxone 
or amoxicillin/clavulanic acid 
Piperacillin/tazobactamΔ
or meropenem§ ± glycopeptide#
Urinary infections Uncomplicated:
or cotrimoxazole
 ciprofloxacin
If sepsis: 
cefotaxime
or ceftriaxone 
or amoxicillin/clavulanic acid
Uncomplicated:
nitrofurantoin or fosfomycin
If sepsis: 
piperacillin/tazobactamΔ
or meropenem§ ± glycopeptide#
Pneumonia** Amoxicillin/clavulanic acid 
or ceftriaxone + macrolide 
levofloxacin
moxifloxacin
or
or
Piperacillin/tazobactam
meropenem/ceftazidime + ciprofloxacin ±
Δ
or
glycopeptide# should be added in patients with risk 
factors for MRSA¶
Cellulitis Amoxicillin/clavulanic acid 
or ceftriaxone + oxacillin
Meropenem/ceftazidime& + oxacillin
or glycopeptides#
SBP, spontaneous bacterial peritonitis; SBE, spontaneous bacterial empyema; MRSA, methicillin-resistant Staphylococcus aureus.
Dosages of antibiotics have not been formally investigated or deﬁned in cirrhotic population and it is advisable to follow standard recommended dosages.
⁄Recommended empirical treatment also for health-care associate (HCA) urinary infections and pneumonia. Empirical antibiotic treatment of HCA spontaneous infections
and cellulitis will be decided on the basis of the severity of infection (patients with severe sepsis should receive the schedule proposed for nosocomial infections) and on the
local prevalence of multiresistant bacteria in HCA infections.
DIn areas with a low prevalence of multiresistant bacteria.
§To cover extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae.
#IV vancomycin or teicoplanin in areas with a high prevalence MRSA and vancomycin-susceptible enterococci (VSE). Glycopeptides must be replaced by IV linezolid in areas
with a high prevalence of vancomycin-resistant enterococci (VRE).
⁄⁄Liver disease is considered as severe comorbidity for community-acquired pneumonia in guidelines.
&Antibiotics active against Pseudomonas aeruginosa.
–Ventilator-associated pneumonia, previous antibiotic therapy, nasal MRSA carriage.
Position PaperCRP, in response to infection [121]. Despite these potential limi-
tations, the predictive power of CRP and PCT for detecting infec-
tion has been found to be similar in patients with and without
cirrhosis (Table 3A) [122–124]. However, as mentioned before
it should be emphasised that CRP levels could remain elevated
over time despite the resolution of bacterial infection in a large
percent of patients with cirrhosis [108]. As far as the deﬁnition
of the severity of the infection, elevated serum levels of PCT
and CRP are correlated with the presence, course, and outcome
of sepsis in patients with cirrhosis (Table 3A) [26] as in the gen-
eral population [125]. Finally, randomized-controlled trials have
shown a beneﬁt from the use of PCT algorithms to guide decisions
about the initiation and/or discontinuation of antibiotic therapy
in patients with some types of infections in the intensive care
unit [126] but its usefulness in patients with cirrhosis has yet
to be investigated.
The role of other acute phase proteins (lipopolysaccharide
binding protein, sCD14) in the early diagnosis as well as in the
deﬁnition of infections in patients with cirrhosis is still unclear,
even thought they are useful predictors of mortality in cirrhosis
[127] mainly when they are used in combination with CRP and
PCT [123]. Recently, mid region-proadrenomedullin has been
shown to provide potentially differential information in infected
patients with cirrhosis compared to CRP [128].
New tools for early identiﬁcation of the pathogen
With regard to the identiﬁcation of the pathogen, real time PCR
assays [129,130] were shown to have potential utility compared
with standard culture techniques for the diagnosis of SBP in
patients with cirrhosis [131]. However, they provide information
not entirely interchangeable with cultures for pathogen identiﬁ-1318 Journal of Hepatology 2014cation [131] (Table 3B). In addition, these molecular assays are
expensive and time-consuming and they need special equipment
and technical expertise for DNA extraction. Considering all these
limitations they may not be suitable as a replacement of cultures
for routine use in clinical practice. Recently, the application of a
direct susceptibility testing (DST) based on a Matrix Assisted
Laser Desorption Ionization – Time of Flight (MALDI-TOF) from
positive blood cultures has been proposed for early detection of
resistant bacteria and their antibiotic susceptibility (Table 3B)
[132,133].
Treatment of bacterial infections in cirrhosis
Antibiotic treatment
Early diagnosis and prompt initiation of adequate antibiotic ther-
apy is essential in the management of patients with cirrhosis and
bacterial infections [1,134] as delays and inappropriate therapy is
associated with increased mortality [135]. The choice of initial
empirical antibiotics should be based on the type, severity and
origin of infection (community-acquired, nosocomial or health
care-associated; HCA) and on the local epidemiological data
about antibiotic resistance. In general, third-generation cephalo-
sporins continue to be the gold-standard antibiotic treatment of
many of the infections acquired in the community [136,137].
By contrast, the empirical treatment of nosocomial and health-
care associated infections should be tailored according to the
local epidemiological pattern of MR bacteria (Table 4) [1,138].
The failure of response to empirical antibiotics is due to inappro-
priate choice of initial antibiotics, MR bacterial infections and
delayed start of appropriate antibiotics [135,138]. If the causativevol. 60 j 1310–1324
Table 5. Current indications of antibiotic prophylaxis in cirrhosis.
Indication Antibiotic and dose
Preserved liver function: norfloxacin 400 mg/12h PO for 7 daysGastrointestinal bleeding
Patients with advanced cirrhosis (at least 2 of the following: ascites, jaundice, hepatic 
encephalopathy and malnutrition): IV ceftriaxone 1 g/d during 7 days 
Primary prophylaxis of SBP in 
patients with low protein ascites 
(<15 g/L)
advanced cirrhosis:
Norfloxacin 400 mg/d PO or ciprofloxacin 500 mg/d until liver transplantation or death in patients with
Norfloxacin 400 mg/d PO until liver transplantation, death, resolution of ascites or improvement in
- Child-Pugh score ≥9 points with serum bilirubin ≥3 mg/dl
and/or
- Renal dysfunction (serum creatinine ≥1.2 mg/dl, BUN ≥25 mg/dl and/or 
serum sodium ≤130 mEq/L)
Secondary prophylaxis of SBP
liver function to a compensated status
JOURNAL OF HEPATOLOGYorganism is identiﬁed (about 50% of cases), antibiotic regimen
should be narrowed to decrease the likelihood of emergence of
antibiotic resistance. Duration of antimicrobial treatment has
not been formally investigated or deﬁned in cirrhosis, except
for SBP with a minimum of 5 days [139]. In SBP, response to anti-
microbials, arbitrarily deﬁned by a P25% reduction of ascitic
polymorphonuclear count, should be assessed by follow-up par-
acentesis 48 h after initial diagnosis [138]. In the case of failure
of response, initial antibiotics should be changed.
Intravenous albumin
In patients with cirrhosis and SBP without shock treated with cef-
otaxime, an open-label randomized clinical trial (RCT) showed
that the IV administration of 20% albumin reduced the incidence
of renal failure and decreased mortality rates from 29% to 10%
[93]. The mechanisms by which albumin improved hemodynam-
ics could be related to its oncotic properties but also to the immu-
nomodulation, antioxidant and endothelium stabilization
capacity [140]. This effect was not observed in patients with
low risk of mortality (total bilirubin <4 mg/dl and creatinine
<1 mg/dl) [141,142]. In a recent randomized study, the adminis-
tration of albumin in unselected patients with cirrhosis and non-
SBP infections was not associated with improved overall survival
but albumin administration was an independent predictor of sur-
vival after adjustment for other prognostic factors [143]. A large
study is currently being planned.
Management of severe sepsis and septic shock
At this time, due to lack of data in cirrhosis, current guidelines
deﬁned in the general population should be followed [144].
Although therapeutic goals for severe sepsis and septic shock in
patients with cirrhosis have not been deﬁned, a prompt (within
the 6 ﬁrst hours) protocolized resuscitation of sepsis-induced
hypoperfusion with pre-deﬁned targets (central venous pressure
8–12 mmHg, urine output P0.5 ml.kg.hr and superior vena cava
or mixed venous saturation 70% or 65% respectively) and normal-
ization of increased lactate levels is recommended. Studies spe-
ciﬁcally investigating the ideal target level of mean arterial
pressure in these patients have not been performed. However,
it appears reasonable to state that arterial pressure should be
increased to a level close to the baseline of each patient, if known.
If not known, it should be at least of 65 mmHg. The balance
between ﬂuid therapy (crystalloids and albumin) and vasopressor
administration in the hemodynamic support of cirrhotic patientsJournal of Hepatology 2014is undeﬁned. A strict monitoring of patients’ responsiveness to
ﬂuid replacement (i.e., pulse pressure variation and stroke vol-
ume variation in sedated patients) is necessary to avoid ﬂuid
overload, peripheral edema and abdominal compartment
syndrome.
Current guidelines only recommend stress dose steroids in
patients with vasopressor-unresponsive septic shock in the gen-
eral population [145]. Data in patients with cirrhosis is scant
and controversial [146,147]. A large double-blind European RCT
is currently underway to address this topic.
Prophylaxis of bacterial infections
Since most episodes of spontaneous bacterial infections in cirrho-
sis are the result from the translocation of enteric gram-negative
bacilli, prophylactic agents should be effective at decreasing the
concentration of these bacteria in the gut while preserving the
protective anaerobic ﬂora. Norﬂoxacin, a poorly absorbable quin-
olone that eliminates gram-negative bacilli selectively from the
intestinal ﬂora, has been used in the prophylaxis of bacterial
infections in cirrhosis. However, given the risk of developing
resistant organisms, the use of prophylactic antibiotics must be
strictly restricted to patients at high risk of bacterial infections
such as patients with upper gastrointestinal bleeding, patients
with advanced cirrhosis and low total protein content in ascitic
ﬂuid and patients with a previous history of SBP (Table 5)
[135,136,138,148,149].
Gastrointestinal bleeding
Forty-ﬁve to 66% cirrhotic patients with upper gastrointestinal
bleeding develop bacterial infection within the ﬁrst 5–7 days of
the bleeding episode [150,151]. The administration of oral or sys-
temic antibiotics (penicillins, cephalosporins, and quinolones)
decreases the incidence of bacterial infections to 10–20%, [152–
154] improves control bleeding, prevents rebleeding and
improves survival [152]. Oral norﬂoxacin (400 mg/12 h for
7 days) is the gold standard prophylaxis in patients with pre-
served liver function. Nevertheless, patients with advanced cir-
rhosis (at least two of the following: ascites, severe
malnutrition, encephalopathy or jaundice) should receive IV cef-
triaxone (1 g/day for 7 days) [1]. In a RCT, the probability of
developing proven infection was signiﬁcantly lower in patients
receiving ceftriaxone iv than in those receiving norﬂoxacin per
os (11% vs. 26%, p = 0.03) [152]. In patients with recent infection
with extended-spectrum b-lactamase-producing Enterobacteria-vol. 60 j 1310–1324 1319
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ceae (3–6 months), antibiotics such as oral nitrofurantoin or
ertapenem should be used. Antibiotic prophylaxis should ideally
be given before or immediately after endoscopy [153].
Primary prophylaxis in advanced cirrhosis
Patients with low protein ascites (10–15 g/L), liver failure (serum
bilirubin >3.2 mg/dl) and low platelet count (<98,000 mm3)
have a high risk of developing the ﬁrst episode of SBP
[1,3,135,150,155]. A RCT evaluated the impact of primary pro-
phylaxis with norﬂoxacin in cirrhotic patients at high risk of
developing SBP and hepatorenal syndrome. Patients with low
protein ascites (<15 g/L) and advanced liver failure (Child-Pugh
score P9 points with serum bilirubin P3 mg/dl) or impaired
renal function (serum creatinine P1.2 mg/dl, BUN P25 mg/dl
or serum sodium 6130 mEq/L) were randomized to receive nor-
ﬂoxacin (400 mg/d for 1 year) or placebo. Norﬂoxacin reduced
the 1-year probability of developing SBP (7% vs. 61%) and hepato-
renal syndrome (28% vs. 41%, p = 0.02) and improved 3-month
survival (94% vs. 62%) [154]. Long-term norﬂoxacin administra-
tion is therefore indicated in this speciﬁc subpopulation of
patients with advanced cirrhosis, particularly if they are awaiting
liver transplantation. Oral ciproﬂoxacin 500 mg/d is an alterna-
tive option to norﬂoxacin [1].
Secondary prophylaxis
Patients who recover from a previous episode of SBP are at a very
high risk of SBP recurrence in the absence of antibiotic prophy-
laxis. Long-term norﬂoxacin administration (400 mg/d PO) is
effective in the prevention of SBP recurrence. Long-term norﬂox-
acin prophylaxis was shown to decrease the overall probability of
SBP recurrence at 1 year from 68% in the placebo group to 20%
and from 60% to 3% respectively if analysis was restricted to
SBP caused by gram-negative bacilli [155]. After an episode of
SBP, liver transplantation must be considered [1].
Infections caused by multiresistant bacteria. The need for alternative
strategies
Prolonged antibiotic administration leads to the emergence of
resistant bacteria. Epidemiological studies have demonstrated
that long-term norﬂoxacin prophylaxis increases the risk of infec-
tions caused by quinolone-resistant, trimethoprim-sulfamethox-
azole-resistant and ESBL-producing strains in cirrhosis [4,20].
Long-term norﬂoxacin prophylaxis increases 2.7 fold the risk of
developing MR bacterial infections and almost 4 fold the risk of
infections caused by ESBL-producing Enterobacteriaceae [3,4,20].
Rifaximin, an antibiotic with broad-spectrum antimicrobial
activity that eliminates intestinal ﬂora non-selectively [156],
has been suggested as a potential alternative to norﬂoxacin in
the prophylaxis of bacterial infections in cirrhosis. Its administra-
tion in patients with hepatic encephalopathy is not associated
with the development of infections by MR bacteria [157]. Three
main characteristics of rifaximin can explain this ﬁnding: (1) it
reaches high fecal concentrations but is virtually non-absorbed
(bioavailability in blood after oral administration <0.4%); (2) it
reduces the expression of bacterial virulence factors and compro-
mises plasmid transfer, an important mechanism of multiresis-
tance; (3) despite high gut concentrations and its broad
spectrum of activity, rifaximin produces minimal alterations in1320 Journal of Hepatology 2014the intestinal microﬂora (1 log reduction in intestinal coliforms
per gram of stool after 2 weeks of treatment) [156–158]. A
case-control study has recently found a signiﬁcant beneﬁt for rif-
aximin for prophylaxis of SBP when used in patients with
encephalopathy [157]. Risk of Clostridium difﬁcile was not
increased [157]. Despite these data, real efﬁcacy and safety of rif-
aximin in the prevention of spontaneous bacterial infections in
cirrhosis remains to be explored. Nevertheless, it should be
emphasized that there are no studies comparing rifaximin vs.
norﬂoxacin in the prevention of SBP.
Non-antibiotic strategies have been studied as a potential
alternative to quinolones in the prophylaxis of bacterial infec-
tions in cirrhosis but evidence published so far is still limited
[159–161,54,162]. Although these strategies seem to prevent
bacterial translocation and SBP in experimental models, none of
them has been compared with norﬂoxacin in the prevention of
SBP in RCT in patients with cirrhosis.Future research and conclusions
It has become clear that cirrhotic patients are susceptible to bac-
terial infections due to a variety of possible pathogenic mecha-
nisms as highlighted. In a recent study, the occurrence of
infection in a cirrhotic patient was suggested to represent a crit-
ical step in the progression of cirrhosis [6]. Gut dysbiosis,
increased bacterial translocation and cirrhosis-associated
immune dysfunction play important roles. The main research
efforts will be the generation of models and possible biomarkers
to identify high-risk patients and the associated mechanisms to
allow preventative strategies. The cirrhotic patient with superim-
posed infection is more susceptible to its effects with increased
risk of end-organ dysfunction and mortality. Future research
should try to dissect the associated mechanisms and devise strat-
egies to reduce this end-organ sensitivity while maintaining
immune competence. The diagnosis of infection in cirrhosis is dif-
ﬁcult because of the co-incident systemic inﬂammatory response
that may exist due to the disease process itself rendering current
markers ineffective resulting in delayed diagnosis. Development
of biomarkers that can be used early will result in a reduction
in the morbidity and mortality. Infection with multi-drug resis-
tant bacteria is increasing possibly due to reduced immune sur-
veillance and inappropriate use of broad-spectrum antibiotics.
Newer tools to detect the kind of infection will limit the use of
broad-spectrum antibiotics and possibly reduce the incidence of
multi-resistant bacterial infections. Better selection of patients
for antibiotic prophylaxis and development of non-antibiotic
strategies will be the key to improving the outcome of patients.
Management of the acute episode of infection and use of albumin
has already yielded good results in spontaneous bacterial perito-
nitis, and trials will be needed for other infections. It is clear that
a concerted program of activity is necessary to address these
pending questions.Conﬂict of interest
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